ReShape Lifesciences Inc. (RSLS)
- Previous Close
0.1681 - Open
0.1740 - Bid --
- Ask --
- Day's Range
0.1686 - 0.1825 - 52 Week Range
0.1410 - 2.7980 - Volume
171,996 - Avg. Volume
500,769 - Market Cap (intraday)
4.175M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9100 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
www.reshapelifesciences.comRecent News: RSLS
Performance Overview: RSLS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RSLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RSLS
Valuation Measures
Market Cap
3.94M
Enterprise Value
-253.86k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.12
Price/Book (mrq)
0.59
Enterprise Value/Revenue
-0.03
Enterprise Value/EBITDA
0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-131.22%
Return on Assets (ttm)
-83.92%
Return on Equity (ttm)
-220.59%
Revenue (ttm)
8.68M
Net Income Avi to Common (ttm)
-11.39M
Diluted EPS (ttm)
-1.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.46M
Total Debt/Equity (mrq)
3.93%
Levered Free Cash Flow (ttm)
-11.7M